



Amendments to the Specification:

Please amend the Abstract as follows:

This invention concerns compounds of formula



~~[[a]]N-oxides, [[a]] pharmaceutically acceptable addition salts, [[a]] quaternary amines and [[a]] stereochemically isomeric forms thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R¹ represents hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyl; C₁₋₆alkyloxycarbonyl; C₁₋₆alkyl substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyloxy; or optionally substituted C₁₋₆alkyloxyC₁₋₆alkylcarbonyl; X₁ represents a direct bond; (CH₂)_{n3} or -(CH₂)_{n4}-X_{1a}-X_{1b}; R² represents optionally substituted C₃₋₇cycloalkyl; phenyl; a 4, 5, 6 or 7 membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N; benzoxazolyl or a radical of formula~~



~~X₂ represents a direct bond; NR¹; NR¹(CH₂)_{n3}; O; O(CH₂)_{n3}; C(=O); C(=O)(CH₂)_{n3}; C(=O)NR⁵(CH₂)_{n3}; C(=S); S; S(=O)_{n1}; (CH₂)_{n3}; -(CH₂)_{n4}-X_{1a}-X_{1b}; X_{1a}-X_{1b}(CH₂)_{n4}; S(=O)_{n1}-NR⁵(CH₂)_{n3}-NR⁵ or S(=O)_{n1}-NR⁵(CH₂)_{n3}; R³ represents an optionally substituted 5 or 6 membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, or a 9 or 10 membered bicyclic heterocycle containing at least one heteroatom selected from O, S or N; R⁴ represents hydrogen; halo; hydroxy; optionally substituted C₁₋₄alkyl; optionally substituted C₂₋₄alkenyl or C₂₋₄alkynyl; polyhaloC₁₋₃alkyl; optionally substituted C₁₋₄alkyloxy; polyhaloC₁₋₃alkyloxy; C₁₋₄alkylthio; polyhaloC₁₋₃alkylthio; C₁₋₄alkyloxycarbonyl; C₁₋₄alkylcarbonyloxy; C₁₋₄alkylcarbonyl; polyhaloC₁₋₄alkylcarbonyl; nitro; cyano; carboxyl; NR⁹R¹⁰; C(=O)NR⁹R¹⁰; NR⁵C(=O)NR⁹R¹⁰; NR⁵C(=O)R⁵; S(=O)_{n1}R¹¹; NR⁵S(=O)_{n1}R¹¹; S-CN; NR⁵CN; their use, pharmaceutical compositions comprising them, and processes for their preparation.~~